Biological Agents on Psoriasis Treatment in Greece


  • Georgia Kokla
  • Petros Galanis
  • Dafni Kaitelidou
  • Enkeleint Aggelos Mechili
  • Olga Archangelidi
  • Marianna Diomidous

J Turk Acad Dermatol 2016;10(4):0-0


Psoriasis is an autoimmune chronic inflammatory disorder of the skin with a 2 - 4% frequency of occurrence worldwide. The plaque psoriasis appears to be the most common form of the disease with an 85% frequency of occurrence. The biological drugs are considered as a revolutionary therapeutical treatment of the chronic inflammatory disease common as gastroenterology, rheumatology and dermatology in the last decade.

Material and Methods:

The objective of this study was, firstly the estimation of the Psoriasis Area and Severity Index (PASI) score of the Greek patients.


The sample consisted of 65 patients (32 men and 33 women) with mean age as 50.2 years. 36.9% of patients (n=24) received the Adalimumab drug for the treatment of psoriasis. Adalimumab received by 33.8% of patients (n = 22) who used the agent Ustekinumab, and finally 29.2% (n=19) of patients used Etanercept. PASI score for the first visit was 5.22, and for the second visit was 3.02.


Consequently, different treatments affect in a different way the PASI score of the patient. The agent Adalimumab had the greatest statistically significant difference between the PASI score of the first and second visit (first visit's PASI: 5.12, second visit's PASI 2.28).

Keywords: Psoriasis, PASI score, biological agents, cost effectiveness